Zimbabwe has declined a major US health deal worth $367m (272 million pounds) spanning five years over Washington's insistence on sensitive information.
The decision became public after a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa deemed the deal was "skewed".
An official spokesperson has since clarified that the United States was demanding access to biological samples for scientific study and commercial gain but refused to guarantee the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable process of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had donated over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for more talks to find a agreement acceptable to both sides so the country's critical HIV treatment initiative can continue.
Wider Implications
Zimbabwe's decision comes after a similar case in Kenya, where a high court halted a similar health funding agreement after concerns were filed about the safety of Kenyans' medical information.
Since returning to office last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking direct bilateral deals to enhance transparency and responsibility.
As per reports, Sixteen African countries have to date agreed to these new health pacts, representing over $18.3bn in new funding.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy via American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to provide its biological resources and data over an extended period, with no equivalent guarantee of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Effectively, our country would supply the raw materials for medical research without any assurance that the final treatments would be available to our population if a new pandemic emerge."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one deals were undermining structures previously established through the international organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to deal with potential pandemics.
"This system is designed to ensure that when a country provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the capability to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome ongoing discussions with our American counterparts on how subsequent co-operation could be arranged in a way that respects the independence and interests of both nations."
Health Experts Response
A leading public health body stated it recognised the government's concerns, but urged that negotiations need to persist considering much of the nation's HIV programmes relied on external financing.
"In cases where technical issues arise, including those involving data governance or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," it added.
The situation highlights the ongoing tensions between accepting much-needed international aid and safeguarding a country's data in an increasingly data-driven world.